Bone drug should be seen in a new light for its anti-cancer properties

November 05, 2014

Australian researchers have shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that have spread to bone, may also benefit patients with tumours outside the skeleton, including breast cancer.

Several clinical trials - where women with breast cancer were given these drugs (bisphosphonates) alongside normal treatment for early-stage disease - showed that they can confer a 'survival advantage' and inhibit cancer spread in some women, although until now no-one has understood why.

A new study by Professor Mike Rogers, Dr Tri Phan and Dr Simon Junankar from Sydney's Garvan Institute of Medical Research has used sophisticated imaging technologies to reveal that bisphosphonates attach to tiny calcifications in tumours in mice.

These calcium-drug complexes are then devoured by 'macrophages', immune cells that the cancer hijacks early in its development to conceal its existence.

The study, which includes remarkable movies of the entire process described above, is published in the prestigious journal Cancer Discovery, now online.

The authors, who also analysed tissue samples from cancer patients, believe that the findings are relevant to people.

"We do not yet fully understand how the macrophages revert from being 'bad cops' to being 'good cops', although it is clear that this immune cell interacts with tumours, and probably changes its function in the presence of bisphosphonates," said project leader Professor Mike Rogers.

"The surprising thing is that we didn't make the connection between bisphosphonates and tumour calcifications before - of course bisphosphonates are going to bind to calcium! It had been staring us in the face for a long time, yet we didn't explore that action of the drug. Perhaps because there is such strong acceptance that these drugs only work in bone."

"When we showed our movies at a conference recently, you could have heard a pin drop in the room - at the same time as the penny dropped for the audience."

Colleague Dr Tri Phan, an immunologist and microscopist, commented that he did not think such a process could be possible until he saw it with his own eyes.

"I clearly remember the moment we first saw macrophages behaving like little Pacmen and gobbling up the drug. It was astounding," he said.

"Our next step will be to analyse the changes that take place in macrophages, so that we can understand their change in function, and effect on cancer cells."

Once Rogers and his colleagues realised what was happening in mice, they worked with colleagues at St Vincent's Hospital in Sydney, and obtained a tumour sample from a patient with breast cancer who had undergone surgery. They stained the tissue for calcifications, and found them next to and even inside macrophages, indicating that the same process happens in humans.

"This study is potentially transformative for treatment of some cancers, because it is telling us for the first time that drugs we thought acted only in bone can also act within tumours completely outside the skeleton, and have a beneficial effect," said Professor Rogers.

"We already know this drug is well-tolerated in people and provides a survival advantage for some patients with certain cancers when taken early in disease development. This now provides a rationale for using these drugs in a different, and potentially more effective, way in the clinic."
-end-


Garvan Institute of Medical Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.